Erez Vigodman and Yitzhak Peterburg will be appointed for three-year terms.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) is nominating Strauss Group president and CEO Erez Vigodman and former Cellcom president and CEO Yitzhak Peterburg as directors. The nominations are included in the Teva's invitation for its upcoming shareholders meeting on June 22. The shareholders will be asked to approve Vigodman's appointment. The directors will be appointed for three-year terms.
Vigodman's resignation from Strauss Group Ltd. (TASE:STRS) will come into effect in October, when he will be replaced by Gadi Lesin. Peterburg has a Ph.D. in health administration from Columbia University and an M.Sc. in Analysis, Design and Management of Information Systems from the London School of Economics. Before joining Cellcom Israel Ltd. (NYSE:CEL; TASE:CEL), he was director general of Clalit Health Services.
Teva is also nominating for new terms vice chairman Dr. Phillip Frost, Roger Abravenel, who has been a director since January 2007, and Teva North America director Elon Kohlberg.
Published by Globes [online], Israel business news - www.globes-online.com - on May 10, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009